Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients

13 Feb 2024

Abstract excerpt

The response rate of anti-PD1 therapy is limited, and the influence of anti-PD1 therapy on cancer patients is unclear. To address these challenges, we conducted a longitudinal analysis of plasma proteomic changes with anti-PD1 therapy in non-small cell lung cancer (NSCLC), alveolar soft part sarcoma (ASPS), and lymphoma patients. We included 339 plasma samples before and after anti-PD1 therapy from 193 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38349411
DOI: 10.1007/s00262-024-03631-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patientsPMID 38349411Read ↗

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapySemantic proximity Read ↗

Blood-based Genomic and Cellular Determinants of Response to Neoadjuvant PD-1 Blockade in Patients with Non-Small-Cell Lung CancerSemantic proximity Read ↗

Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB)Semantic proximity Read ↗

In-depth proteomic analysis identifies key gene signatures predicting therapeutic efficacy of anti-PD-1/PD-L1 monotherapy in non-small cell lung cancerSemantic proximity Read ↗

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity Read ↗

Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockadeSemantic proximity Read ↗

Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studySemantic proximity Read ↗

Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

Serum Proteomic Profile of Advanced NSCLC and Exploration of Efficacy Markers for Anti-Angiogenic DrugsSemantic proximity Read ↗

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implicationsSemantic proximity Read ↗

Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.